Anavex Lf SC (AVXL) Stock Price, Quote & News

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-c...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 689 3939

Website: www.anavex.com

Address:

630 5th Avenue, 20th Floor, New York, United States

Orion33 May. 13 at 12:18 PM

$AVXL AVXL earnings on 5-18-26 EST after market - VIA Schwab. ( Hope this information is crrect )

2 · Reply

AntonioChigurh May. 13 at 11:11 AM

$AVXL i’m out. Dead money until 2030 if ever. Already recovering huge losses quick riding the Ai wave. Never fall in love with a stock.

1 · Reply

Georgejj May. 13 at 3:13 AM

$AVXL Axsome Therapeutics could be an excellent partner for Anavex Life Sciences for blarcamesine Good luck and GOD bless,

0 · Reply

DueBill May. 13 at 1:04 AM

$AVXL Looking at your posts…. You really don’t “pick ‘em well now do you 🤣

0 · Reply

Silo46 May. 12 at 8:44 PM

$AVXL Is the” $100 soon” crowd still around?

5 · Reply

hossticklephifer May. 12 at 7:42 PM

$AVXL shorts are going to eat this company up, as they should. POS

2 · Reply

TTTav66 May. 12 at 6:29 PM

$AVXL Anavex SVP & Global Head of Neurology Dr. Wolfgang Liedtke is presenting a poster at the Tau Global Conference in Washington DC (May 14-15): “Anavex®3-71, A Dual Sigma1-R M1-Agonist, Targets Upstream Drivers Of Tau Pathology And Features Benign Human Safety.” https://www.alz.org/tau

2 · Reply

Sand_Pebble May. 12 at 6:04 PM

$AVXL it's official, Dr Markary is out at FDA, supposedly due to his opposition to the flavored vapes & slow action on an abortion pill. Nothing to do with Blarcamesine. We lost our inside man. 🙁

2 · Reply

NorvaK May. 12 at 4:09 PM

$AVXL Sold Out yesterday. Greatest feeling of relief. You live, you learn!!!! Still young in my 30’s to recover my Missling losses. Science is promising, i’ll check back in 2030.

2 · Reply

kitty7kitty May. 12 at 4:00 PM

$AVXL WHEN is there going to be a CC? Unless this happens, it is just more deception.

1 · Reply

Anavex delays 10Q filing

2026-05-07T04:34:31.000Z - 6 days ago

Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling

May 6, 2026, 7:00 AM EDT - 7 days ago

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

2026-05-04T11:06:52.000Z - 9 days ago

Anavex initiated with a Buy at Rodman & Renshaw

Apr 14, 2026, 1:30 PM EDT - 4 weeks ago

Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 7:30 AM EDT - 4 weeks ago

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease

Apr 7, 2026, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-30T11:49:59.000Z - 6 weeks ago

Anavex gives update after blarcamesine marketing authorization withdrawal

Mar 30, 2026, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Provides Comprehensive Regulatory Update

2026-03-25T11:40:45.000Z - 7 weeks ago

Anavex withdraws marketing authorization application for blarcamesine in the EU

Mar 25, 2026, 7:30 AM EDT - 7 weeks ago

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

2026-03-23T11:45:08.000Z - 7 weeks ago

Anavex presents new data from ANAVEX2-73-AD-004 program

Mar 23, 2026, 7:30 AM EDT - 7 weeks ago

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease

Mar 20, 2026, 7:30 AM EDT - 7 weeks ago

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease

2026-03-17T11:40:32.000Z - 2 months ago

Anavex presents treatment effects of blarcamesine in Parkinson’s model

Mar 17, 2026, 7:30 AM EDT - 2 months ago

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference

Mar 3, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Mar 2, 2026, 11:50 AM EST - 2 months ago

Anavex Life Sciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

2026-02-23T12:45:54.000Z - 2 months ago

Anavex appoints Paeger to Board of Directors

Feb 23, 2026, 7:30 AM EST - 2 months ago

Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

Feb 9, 2026, 8:30 AM EST - 3 months ago

Anavex Life Sciences Earnings Call Transcript: Q1 2026

Feb 9, 2026, 7:30 AM EST - 3 months ago

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Feb 3, 2026, 7:30 AM EST - 3 months ago

Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Jan 14, 2026, 7:30 PM EST - 4 months ago

Anavex Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-13T12:41:18.000Z - 4 months ago

Anavex joins ACCESS-AD, initiative for therapeutic approaches for Alzheimer’s

Jan 13, 2026, 7:30 AM EST - 4 months ago

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease

2026-01-08T12:35:17.000Z - 4 months ago

Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron

REGN

Jan 8, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

2026-01-06T12:36:17.000Z - 4 months ago

Anavex receives FDA feedback on Alzheimer’s disease program

Jan 6, 2026, 7:30 AM EST - 4 months ago

Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program

2025-12-18T12:35:52.000Z - 5 months ago

Anavex submits request for EMA to re-examine its opinion on blarcamesine

Dec 18, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

2025-12-16T18:20:16.000Z - 5 months ago

Anavex participates in a conference call with H.C. Wainwright

2025-12-12T21:15:18.000Z - 5 months ago

Anavex announces negative CHMP opinion on blarcamesine MAA

Nov 26, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 25, 2025, 8:30 AM EST - 6 months ago

Anavex Life Sciences Earnings Call Transcript: Q4 2025

Nov 25, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Nov 19, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Nov 18, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Nov 14, 2025, 7:30 AM EST - 6 months ago

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group

Oct 10, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'

Oct 2, 2025, 7:35 AM EDT - 7 months ago

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

Oct 2, 2025, 7:30 AM EDT - 7 months ago

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial

Sep 9, 2025, 1:00 PM EDT - 8 months ago

Anavex Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial

Sep 2, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Aug 26, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

Aug 20, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Anavex Life Sciences Earnings Call Transcript: Q3 2025

Aug 12, 2025, 7:30 AM EDT - 9 months ago

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

Aug 5, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

May 14, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 8:30 AM EDT - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q2 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Anavex Life Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 5, 2025, 11:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 9:50 AM EST - 1 year ago

Anavex Life Sciences Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:30 AM EST - 1 year ago

Anavex Life Sciences Earnings Call Transcript: Q1 2025

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 1 year ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Orion33 May. 13 at 12:18 PM

$AVXL AVXL earnings on 5-18-26 EST after market - VIA Schwab. ( Hope this information is crrect )

2 · Reply

AntonioChigurh May. 13 at 11:11 AM

$AVXL i’m out. Dead money until 2030 if ever. Already recovering huge losses quick riding the Ai wave. Never fall in love with a stock.

1 · Reply

Georgejj May. 13 at 3:13 AM

$AVXL Axsome Therapeutics could be an excellent partner for Anavex Life Sciences for blarcamesine Good luck and GOD bless,

0 · Reply

DueBill May. 13 at 1:04 AM

$AVXL Looking at your posts…. You really don’t “pick ‘em well now do you 🤣

0 · Reply

Silo46 May. 12 at 8:44 PM

$AVXL Is the” $100 soon” crowd still around?

5 · Reply

hossticklephifer May. 12 at 7:42 PM

$AVXL shorts are going to eat this company up, as they should. POS

2 · Reply

TTTav66 May. 12 at 6:29 PM

2 · Reply

Sand_Pebble May. 12 at 6:04 PM

$AVXL it's official, Dr Markary is out at FDA, supposedly due to his opposition to the flavored vapes & slow action on an abortion pill. Nothing to do with Blarcamesine. We lost our inside man. 🙁

2 · Reply

NorvaK May. 12 at 4:09 PM

$AVXL Sold Out yesterday. Greatest feeling of relief. You live, you learn!!!! Still young in my 30’s to recover my Missling losses. Science is promising, i’ll check back in 2030.

2 · Reply

kitty7kitty May. 12 at 4:00 PM

$AVXL WHEN is there going to be a CC? Unless this happens, it is just more deception.

1 · Reply

Sand_Pebble May. 12 at 3:43 PM

$AVXL I hate to say it folks but unless some random news is released, something no one is expecting soon, I don’t think 2.61 is going to be our 5 year low.

0 · Reply

DueBill May. 12 at 1:43 PM

$AVXL No Shit 🤦‍♂️ https://www.foxnews.com/health/alzheimers-drugs-slammed-ineffective-major-review-critics-push-back

1 · Reply

Woundntyouliketoknow May. 12 at 1:08 PM

$AVXL Institutional Ownership 45.70% Source: https://www.nasdaq.com/market-activity/stocks/avxl/institutional-holdings

1 · Reply

Trainguy1 May. 12 at 1:01 PM

$AVXL @MayoMobile Hey MayoMobile, I noticed two years and two months have passed since the FDA released this draft guidance document on Early Alzheimer's Disease Drug Development: https://www.fda.gov/media/110903/download. Did the FDA ever follow up with you on SOTC's public comments? I'm wondering where the FDA is going with the document.

1 · Reply

Georgejj May. 12 at 2:37 AM

$AVXL FORM 12b-25 NOTIFICATION OF LATE FILING https://www.sec.gov/Archives/edgar/data/1314052/000173112226000702/e7626_nt10-q.htm Good luck and GOD bless,

1 · Reply

SCLXSUX May. 12 at 12:51 AM

$AVXL - "Mistakes"? Missling made more than a few errors while being the head of the company, and more than likely delayed / postponed approval by years. And as far as "standing strong" goes, he was compensated handsomely for his efforts. Just my 2-Cents.

1 · Reply

Bradi2i May. 11 at 10:38 PM

$AVXL I did nop research just had AI make a list for me - where to start for the next CEO Top 10 Influential Neuroscientists (USA & Europe)ScientistInstitutionLocationCore ExpertiseSolomon H. SnyderJohns Hopkins UniversityUSANeuropharmacology & NeurotransmittersKarl J. FristonUniversity College LondonUKTheoretical Neuroscience (Free Energy Principle)David GintyHarvard Medical SchoolUSASomatosensation (Touch & Pain) — 2026 Brain Prize WinnerKarl DeisserothStanford UniversityUSAOptogenetics & Hydrogel-tissue Chemistry (CLARITY)Patrik ErnforsKarolinska InstituteSwedenSensory Neuron Systems — 2026 Brain Prize WinnerFred H. GageSalk InstituteUSANeurogenesis & Genomic Diversity in the BrainKaj BlennowUniversity of GothenburgSwedenBiomarkers for Alzheimer’s DiseaseMichelle MonjeStanford UniversityUSACancer Neuroscience — 2025 Brain Prize WinnerHaim SompolinskyHarvard / Hebrew Univ.USA/IsraelComputational & Theoretical NeuroscienceTrevor W. RobbinsUniversity of Cambridge

0 · Reply

Bradi2i May. 11 at 10:35 PM

$AVXL It could take a year to get a great CEO to fill Missling's shoes. Despite his "mistakes", he stood strong for AVXL for many years. I say adiose you are appreciated by many of the shareholders. This is a difficult disease, many companies have failed and ran with their tails between their legs. Please BOD's, avoid just filling the slot with some re-cycled Biotech manager. We need someone who looks to the future, not repairing the past.

0 · Reply

Kb1123 May. 11 at 9:10 PM

$AVXL dead money for atleast 6 months

4 · Reply

History101 May. 11 at 6:34 PM

$AVXL parkinson's news: https://finance.yahoo.com/sectors/healthcare/articles/zuckerberg-backed-cellular-intelligence-acquires-124238555.html

0 · Reply

Rudedog_1963 May. 11 at 2:16 PM

$AVXL $$$ANAVEX$$$

0 · Reply

SCLXSUX May. 11 at 2:12 PM

$AVXL - Anavex sure knows how to test your faith and patience! I hope our new chapter in this never ending saga of the Good, Bad & Ugly is better than the last. We endured 10-years of Bad, seen some Ugly, and are hoping the Good is just starting!!!

1 · Reply

Market Cap	300.26M
Revenue (ttm)	0.00
Net Income (ttm)	-46.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,236,100
Avg Vol	1,409,864
Day's Range	N/A - N/A
Shares Out	92.67M
Stochastic %K	9%
Beta	1.24
Analysts	Sell
Price Target	$22.00